Kisqali (ribociclib) is a targeted cancer drug that works by blocking two specific proteins, called CDK4 and CDK6, that cancer cells rely on to divide and multiply. It is primarily used to treat hormone receptor-positive (HR+), HER2-negative breast cancer, either in early-stage or advanced disease, and is taken alongside hormone therapy.
How Kisqali Stops Cancer Cells From Dividing
To understand how Kisqali works, it helps to know a little about how cells decide to divide. Healthy cells go through a tightly controlled cycle before they can split into two new cells. One critical checkpoint in that cycle involves a protein called retinoblastoma protein (Rb), which acts like a brake. When Rb is active, it holds onto another protein that would otherwise flip the switch on cell division, keeping the cell in a resting state.
In HR-positive breast cancer, estrogen and other growth signals cause CDK4 and CDK6 to pair up with a partner protein called cyclin D1. That complex essentially releases the Rb brake by adding chemical tags (phosphorylation) to it. Once the brake is released, the cell gets the green light to divide. This pathway is disrupted in the majority of cancers, making it a high-value target for treatment.
Kisqali blocks CDK4 and CDK6 from doing their job. Without those proteins actively disabling the Rb brake, the brake stays on, the cell can’t progress through its cycle, and division stops. The result is that tumor growth slows or halts. Because the drug targets a specific molecular pathway rather than killing all rapidly dividing cells (the way traditional chemotherapy does), it tends to be more precise in its effects.
What Kisqali Is Approved to Treat
Kisqali is approved for HR-positive, HER2-negative breast cancer. It is always used in combination with hormone therapy, not on its own. For advanced or metastatic breast cancer, it is paired with an aromatase inhibitor or another hormonal agent. For early-stage breast cancer, it was approved based on the NATALEE trial, which enrolled over 5,100 patients with higher-risk early disease. That trial defined “higher risk” as cancer that had spread to lymph nodes, or node-negative tumors that were either larger than 5 cm, or 2 to 5 cm with aggressive features like high grade or high genomic risk.
In the early-stage setting, Kisqali is taken at a lower dose (400 mg daily) alongside a nonsteroidal aromatase inhibitor. Some patients, particularly premenopausal women, also receive a medication to suppress ovarian function.
Dosing Schedule and Daily Routine
Kisqali follows a 28-day cycle: 21 days on the drug, then 7 days off. The week-long break gives the body time to recover from the drug’s effects on blood cell production and other tissues. The standard dose is 600 mg per day for advanced or metastatic cancer and 400 mg per day for early-stage cancer, taken once daily as tablets.
You can take Kisqali with or without food. However, there are specific dietary restrictions. Grapefruit, pomegranate, and their juices must be avoided during treatment. These fruits inhibit a liver enzyme (CYP3A) that breaks down Kisqali, so consuming them can cause the drug to build up to higher levels in your blood than intended, increasing the risk of side effects.
Common Side Effects
The most frequently reported side effects of Kisqali are drops in blood cell counts (particularly white blood cells, a condition called neutropenia) and changes in liver function tests. Neutropenia is the main reason for the 7-day break in each cycle, as it allows white blood cell counts to bounce back. Fatigue, nausea, and digestive issues are also common. Your care team will order regular blood tests throughout treatment to monitor blood counts and liver enzymes, and may adjust your dose if levels fall too low.
Heart Rhythm Monitoring
One side effect that sets Kisqali apart from the other CDK4/6 inhibitors is its effect on the heart’s electrical activity. Kisqali can prolong what’s known as the QT interval, a measurement on an electrocardiogram (ECG) that reflects how long it takes the heart to reset between beats. A prolonged QT interval can, in rare cases, lead to dangerous heart rhythms.
A large meta-analysis of clinical trials found that Kisqali had the highest incidence of QT prolongation among the three CDK4/6 inhibitors, with a roughly threefold increased risk compared to control groups. Grade 3 prolongation, the most clinically significant level, was observed exclusively with Kisqali in that analysis. Because of this, you will have ECG monitoring at multiple points during treatment, especially in the first few cycles. This is routine and does not mean problems are expected, but it does mean this particular side effect is taken seriously from the start.
How Kisqali Compares to Other CDK4/6 Inhibitors
Kisqali is one of three CDK4/6 inhibitors available. The other two are palbociclib (Ibrance) and abemaciclib (Verzenio). All three target the same CDK4/6 pathway and are used in HR-positive, HER2-negative breast cancer, but they differ in a few practical ways.
The side effect profiles diverge most notably around heart rhythm and digestive symptoms. Kisqali requires ECG monitoring because of the QT prolongation risk, while palbociclib and abemaciclib generally do not. Abemaciclib is more commonly associated with diarrhea than the other two. All three cause neutropenia, though the severity varies. The choice between them often comes down to the specific clinical situation, side effect considerations, and how the drug fits into a patient’s treatment plan and daily life.